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Abstract: 
 
Validated methods are needed for the analysis of natural product secondary metabolites. These 
methods are particularly important to translate in vitro observations to in vivo studies. Herein, a 
method is reported for the analysis of the key secondary metabolites, a series of flavonolignans 
and a flavonoid, from an extract prepared from the seeds of milk thistle [Silybum marianum (L.) 
Gaertn. (Asteraceae)]. This report represents the first UHPLC MS-MS method validated for 
quantitative analysis of these compounds. The method takes advantage of the excellent 
resolution achievable with UHPLC to provide a complete analysis in less than 7 min. The 
method is validated using both UV and MS detectors, making it applicable in laboratories with 
different types of analytical instrumentation available. Lower limits of quantitation achieved with 
this method range from 0.0400 μM to 0.160 μM with UV and from 0.0800 μM to 0.160 μM with 
MS. The new method is employed to evaluate variability in constituent composition in various 
commercial S. marianum extracts, and to show that storage of the milk thistle compounds in 
DMSO leads to degradation. 
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Article: 
 
1. Introduction 
 
The medicinal herb, milk thistle [Silybum marianum (L.) Gaertn. (Asteraceae)], has been used 
since antiquity, particularly for hepatoprotective applications [1], and more recently, for prostate 
cancer chemoprevention [2]. In the modern herbal pharmacopeia, there are two main milk thistle 
preparations [3]. Silymarin is an extract of the seeds (achenes) and consists of the flavonoid 
taxifolin (1) and at least seven flavonolignans [isosilychristin (2), silychristin (3), silydianin (4), 
silybin A (5), silybin B (6), isosilybin A (7), and isosilybin B (8); Fig. 1], along with other minor 
constituents. This extract can be partially purified to form the other main preparation, termed 
either silybin or silibinin, which is largely a 1:1 mixture of 5 and 6. 
 
Fig. 1. Structures of compounds 1-8. The numerical order of the compounds corresponds to their 
elution order in the MS and UV chromatograms for silymarin extract Madaus 37501. 
 
After over a decade of studying the chemistry of flavonolignans from milk thistle, methods have 
been developed to separate and identify the flavonolignan diastereoisomers on the gram scale 
[4]. This supply, in turn, has assisted with the examination of the cytoprotective properties of the 
milk thistle compounds, where they have demonstrated activity in inhibiting virus infection, 
preventing oxidative stress, and modulating cellular metabolic and inflammatory status [5], [6], 
[7]. For effective studies of the biological activity of milk thistle preparations, both in vitro and 
in vivo, knowledge of the quantity and identity of bioactive constituents in study material is 
needed. To address this need, the purpose of this study was to develop a validated method for the 
quantitative determination of milk thistle compounds in extracts and preparations. 
 
In the past few years, there have been three studies devoted to the chemical characterization of 
milk thistle products. Li et al. [8] developed a 40 min HPLC–MS method for analysis of silibinin 
(a 1:1 mixture of 5 and 6) in plasma. Hadad et al. [9] developed an 8 min HPLC method 
(employing monolithic columns) for analysis of seven compounds from silymarin. The 
compounds were detected by relying on their absorbance at 288 nm. Finally, Wang et al. [10] 
employed UHPLC coupled to electrospray ionization mass spectrometry (ESI–MS) for 
identification of seven compounds from silymarin. Similar to the approach employed by Wang et 
al. [10], the method described herein relies on UHPLC ESI–MS. A major advantage of this 
approach is the rapid analysis times that it facilitates (in this case, 6 min). However, unlike the 
previously published UHPLC ESI–MS method [10], our method is extended to include both 
quantitation and identification. Indeed, herein is the first validated method for quantitative 
analysis of all eight major bioactive components of silymarin (1-8). 
 
2. Experimental 
 
2.1. Materials and chemicals 
 
The seven flavonolignans and taxifolin (Fig. 1) were isolated as described previously [4], and 
were all of a high purity (≥98%) as determined by UHPLC-UV analysis. Constituent levels were 
quantified in a number of different silymarin extracts using the methods described herein. Two 
separate batches of silymarin (product number 345066, lot numbers 37501 and 286061) from 
Euromed, S.A. (Barcelona, Spain), which is a part of the Madaus Group (Cologne, Germany), a 
batch of silymarin from Indena S.p.A. (Milan, Italy) (lot number 27691; the source for the 
isolation of the pure compounds), and two separate batches of silymarin from Sigma-Aldrich (St. 
Louis, MO, USA) (product numbers S0292 and 254924; lot numbers BCBJ0393V and 05503 
PG) were analyzed. Caffeine, HPLC grade acetonitrile, and mass spectrometry grade formic 
acid, methanol (MeOH), and water (H2O) were purchased from Fisher Scientific (Waltham, MA, 
USA). 
 
2.2. Preparation of samples and standards 
 
All compounds were dissolved separately in 1:1CH3CN:H2O (with 655 μM caffeine as internal 
control) to produce 5.24 mM stock solutions. An equimolar master mixture of the eight analytes 
was prepared at concentrations of 655 μM for each individual component (and 655 μM caffeine). 
This master mixture was serially diluted 2-fold to produce 17 standard mixtures ranging in 
concentration from 328 μM to 0.005 μM. A separate series of quality control samples (QC) was 
prepared by separately diluting the 655 μM master mixture to 16.4 μM, 1.64 μM, and 0.164 μM 
(high, medium, and low QCs). A series of silymarin mixtures was prepared in 1:1CH3CN:H2O at 
2.53 mg/mL, and diluted 100-fold prior to analysis. 
 
2.3. UHPLC-UV-MS quantitative analysis 
 
UHPLC analyses were conducted utilizing a Waters Acquity UHPLC system (Milford, MA, 
USA) equipped with an autosampler, photodiode array detector (PDA), column manager, and 
binary solvent manager. An HSS-T3 C18 column (100 mm × 2.1 mm i.d., 1.8 μm packing, from 
Waters) operated at 50 °C was used for all chromatographic analyses. The gradient system 
consisted of 0.1% formic acid in MeOH (B) and 0.1% formic acid in H2O (A), at a flow rate of 
0.5 mL/min. A gradient from 30 to 55% B over 6.0 min followed by reequilibration at 30% B for 
0.6 min was used. All samples and standards were analyzed in triplicate using 3 μL injections, 
with the exception of the QC samples, which were injected in quintuplicate. 
 
The UHPLC system was coupled to a Thermo Scientific TSQ Quantum Access triple quadrapole 
mass spectrometer (Waltham, MA, USA) with a heated electrospray ionization (HESI) source. 
Analyses were conducted in the positive ion mode, with a spray voltage of 3800 V, vaporizer and 
capillary temperatures of 360 °C and 380 °C, respectively, and sheath gas and auxiliary gas of 50 
and 45 (arbitrary units), respectively. Tube lens offset and skimmer offset were 122 V and 0 V, 
respectively. 
 
Quantitative analysis was performed using UV data collected at 288 nm and multiple reaction 
monitoring (MRM) on the mass spectrometer (MS). The UV and MS data were collected 
simultaneously for each injection. MRM transitions employed for each compound are given 
in Table 1. For each analyte, three additional MRM transitions were observed to verify peak 
identity, and a table of the transitions observed during each of the acquisition segments is 
provided (Table S1). UV and MS data were collected and analyzed using Xcaliber software 
(version 2.2, from Thermo Scientific). Peak detection and peak areas were determined using the 
ICIS algorithm for MS data and the Avalon algorithm for UV data. All calibration curves were 
generated in Xcaliber using 1/X weighting to create linear curve fits that emphasize the lower 
concentration calibration points. External calibration was employed for this analysis. 
 
Table 1. Multiple reaction monitoring transitions observed.a 
Analyte Retention time (min) Precursor ion (m/z) Product ion (m/z) Collision energy (eV) 
Caffeine 1.19 195.1 [M+H]+ 138.2 22 
1 1.82 305.1 [M+H]+ 259.1 13 
2 2.70 483.1 [M+H]+ 153.0 22 
3 2.97 453.1 [M-CH2OH + H]+ 435.1 12 
4 3.42 483.1 [M+H]+ 153.0 30 
5 4.79 483.1 [M+H]+ 465.1 10 
6 5.03 483.1 [M+H]+ 465.1 10 
7 5.63 483.1 [M+H]+ 329.0 10 
8 5.79 483.1 [M+H]+ 329.0 10 
a The dwell time for all transitions was 0.040 min. 
 
2.4. Method validation 
 
The identities of the standards were confirmed by NMR and mass spectrometry analyses [4], 
[11], [12], as well as by comparison of elution time with other identified standards. Linearity of 
the calibration curves was assessed by least-squares analysis. Precision and accuracy were 
determined by calculating the relative standard deviation (RSD) and relative error (RE), 
respectively, for replicate injections. For the purpose of this study, RE is defined as the percent 
difference between the mean measured concentration of three replicate injections of each 
standard concentration, and the nominal concentration of that standard. All analyses were 
performed in triplicate on three different days. Repeatability was evaluated based on the RSD 
and RE for triplicate analyses in a single day, while intermediate precision was determined based 
on the interday RSD and RE. The lower limit of quantitation (LLOQ) was defined as the lowest 
concentration of a given analyte that could be measured with an intraday precision below 15%. 
For the MS data analysis, the upper limit of quantitation (ULOQ) was defined as the highest 
concentration where the relationship between MS signal and concentration was linear (as evident 
by R2 > 0.9995). For the UV data analysis, the ULOQ was set at the highest concentration 
measured in this study, as the upper limit for linearity in UV signals was not reached. All 
standard curves were plotted using standard concentrations between, and including, the LLOQ 
and the ULOQ. The linear dynamic range for each analyte was defined as being all 
concentrations between, and including, the LLOQ and the ULOQ. The linearity of all of the UV 
standard curves was verified by each having an R2 > 0.9999. 
 
Sets of high, medium, and low QC samples were placed at the beginning, middle, and end of the 
sample sets for each day of analysis, and the intraday and interday results for RE and RSD were 
measured to verify method and instrument stability across the days of analysis. Caffeine was 
included as an internal control in all standard and QC samples to monitor consistency in 
retention times and linearity of both dilutions and instrument response. 
 
2.5. Matrix effects 
 
Matrix effects were examined by comparison of quantitation results for silymarin samples spiked 
with blank solvent versus the results for the same samples spiked with an equal volume of a 
solution containing all eight of the analytes. Matrix effects were determined by subtracting the 
area for the analyte of interest in the unspiked extract (Amatrix) from the area in the spiked extract 
(Amatrix,spiked), and dividing by the area for the analyte in solvent without matrix (Asolvent) 
(Eq. (1)). 
 
%𝑀𝑀𝑀𝑀 = 100 ×
𝐴𝐴𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚,𝑠𝑠𝑠𝑠𝑚𝑚𝑠𝑠𝑠𝑠𝑠𝑠 − 𝐴𝐴𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚
𝐴𝐴𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑚𝑚
 
(1) 
 
2.6. Evaluation of compound stability 
 
UHPLC analyses were completed utilizing a Waters Acquity UHPLC system similar to the one 
described in Section 2.3. All degraded samples used for this experiment were from the same 
batches of the eight compounds as were used for the validation study. Degraded samples were 
prepared at 500 μM in DMSO from pure (non-degraded) dry stocks of each analyte and stored at 
room temperature for 6 months (191 days) before analysis. The fresh samples of each compound 
were prepared in MeOH from the same dry stocks of the compounds (stored dry at 4°C over the 
same 6 months) immediately before analysis. 
 
3. Results and discussion 
 
3.1. Method validation 
 
Calibration curves for all standards exhibited coefficients of determination (R2) greater than 
0.9995 for MS data (Table 2) and 0.9999 for UV data (Table 3). Baseline resolution of all 
analytes was achieved (Fig. 2). Precision and accuracy for the MS and UV data are given in 
Table 4, Table 5, respectively. For all standard concentrations at or above the MS LLOQ, the 
RSD of all compounds using MS data was below 12% (intraday) and 7.0% (interday); and the 
RE for MS data remained below 7.8% (intraday) and 6.3% (interday) (Table 4). For all standard 
concentrations at or above the UV LLOQ, the RSD for all compounds using UV data was below 
7.2% (intraday) and 8.4% (interday); and the RE for UV data remained below 12% (intraday) 
and 9.2% (interday) (Table 5). These findings indicate sufficient accuracy and precision for a 
validated analytical method. According to the FDA Guidance for Industry: Bioanalytical Method 
Validation, the target values for precision and accuracy of validated methods are ≤ 15% [13]. All 
measurements in the linear dynamic range for each analyte had a precision and accuracy of 
<15% (Table 4, Table 5). 
 
Table 2. Parameters of calibration curves for the MS data. 
Analyte Slope (± SD) × 103 Intercept (± SD) × 103 r2 LLOQa (μM) ULOQb (μM) 
1 973.8 (2.9) 11.7 (12) 0.9998 0.0800 10.2 
2 315.0 (1.7) 1.4 (7.2) 0.9995 0.0800 10.2 
3 1379.5 (4.4) 29.6 (18) 0.9997 0.0800 10.2 
4 376.5 (1.4) −1.1 (6.3) 0.9995 0.160 10.2 
5 822.9 (1.9) 22.3 (7.8) 0.9997 0.0800 10.2 
6 831.4 (3.5) 25.7 (15) 0.9995 0.0800 10.2 
7 798.6 (3.5) 5.9 (15) 0.9996 0.0800 10.2 
8 748.5 (2.4) 2.1 (10) 0.9996 0.0800 10.2 
a Lower limit of quantitation. 
b Upper limit of quantitation. 
 
Table 3. Parameters of calibration curves for the UV data. 
Analyte Slope (± SD) Intercept (± SD) r2 LLOQa (μM) ULOQb (μM) 
1 4495.3 (2.6) 15 (260) 1.0000 0.0400 328 
2 5068.8 (2.8) 9 (280) 1.0000 0.0400 328 
3 5412.3 (3.4) 28 (350) 1.0000 0.0400 328 
4 4460.8 (6.3) −372 (690) 0.9999 0.160 328 
5 5474.8 (2.3) 98 (240) 1.0000 0.0400 328 
6 5790.5 (2.8) 101 (280) 1.0000 0.0400 328 
7 5937.4 (2.9) 67 (290) 1.0000 0.0400 328 
8 5156.0 (2.4) 16 (240) 1.0000 0.0400 328 
a Lower limit of quantitation. 
b Upper limit of quantitation. 
 
 
Fig. 2. MS and UV chromatograms of an equimolar mixture of analytes 1-8 at 10.24 μM and the 
internal standard caffeinea. 
aPeak at 1.19/1.17 min is caffeine, which was added to monitor for drift in response and retention time. 
 
Table 4. Intraday and interday precision and accuracy using MS detection. 
Analyte Concentration of standard solution injected (μM) Intraday Interday 
  RSD (%) RE (%) RSD (%) RE (%) 
 0.0800 2.0 1.9 2.1 0.51 
 0.160 1.2 2.0 1.2 0.65 
 0.320 3.0 1.6 2.4 0.82 
 0.640 2.8 0.73 0.12 0.63 
1 1.28 0.092 1.3 1.6 0.080 
 2.56 0.89 0.19 0.37 0.28 
 5.12 1.0 0.55 0.18 0.39 
 10.2 1.3 0.53 0.34 0.26 
  
 0.0800 7.2 1.6 0.49 2.0 
 0.160 8.2 0.76 2.7 0.28 
 0.320 2.4 1.5 3.0 1.6 
 0.640 1.6 1.4 0.61 2.1 
2 1.28 0.98 2.3 1.1 1.2 
 2.56 1.1 0.054 2.3 0.93 
 5.12 2.5 0.38 1.0 0.074 
 10.2 2.5 0.021 0.24 0.25 
  
 0.0800 0.35 7.8 1.6 6.3 
 0.160 2.8 0.85 1.5 0.64 
 0.320 0.83 0.62 0.99 0.52 
 0.640 1.7 3.8 0.95 3.4 
3 1.28 0.60 2.4 0.51 2.3 
 2.56 0.50 0.47 1.2 0.69 
 5.12 1.6 0.79 0.090 0.89 
 10.2 0.34 1.0 0.36 1.1  
Analyte Concentration of standard solution injected (μM) Intraday Interday 
  RSD (%) RE (%) RSD (%) RE (%) 
 0.160 4.4 6.5 7.0 1.4 
 0.320 3.4 5.6 5.2 0.40 
 0.640 5.1 0.25 0.33 0.012 
4 1.28 2.6 0.55 1.3 0.50 
 2.56 0.45 1.6 1.7 0.37 
 5.12 2.7 0.95 0.70 0.45 
 10.2 0.64 0.056 0.57 0.37 
  
 0.0800 8.0 1.7 2.4 0.20 
 0.160 6.1 7.2 5.7 1.1 
 0.320 1.9 4.4 3.8 0.70 
 0.640 3.1 3.0 1.5 1.3 
5 1.28 1.7 0.019 2.3 0.74 
 2.56 0.45 2.0 1.4 0.59 
 5.12 1.5 0.28 1.1 0.17 
 10.2 0.22 0.41 0.67 0.070 
  
 0.0800 12 0.71 4.5 4.4 
 0.160 9.5 0.0050 1.9 1.4 
 0.320 4.9 1.0 2.3 3.5 
 0.640 4.9 0.79 4.3 1.0 
6 1.28 2.9 1.5 0.66 1.0 
 2.56 2.4 1.2 0.87 0.30 
 5.12 1.5 0.24 0.63 0.33 
 10.2 1.9 0.032 0.55 0.079 
  
 0.0800 3.7 5.9 5.9 1.5 
 0.160 7.9 4.3 3.0 1.3 
 0.320 3.1 3.0 1.7 1.1 
 0.640 3.2 1.3 2.0 0.98 
7 1.28 0.11 0.12 1.5 0.22 
 2.56 1.3 0.92 0.92 0.75 
 5.12 2.1 1.7 0.50 1.2 
 10.2 1.5 0.59 0.56 0.38 
  
 0.0800 4.5 2.7 0.94 1.9 
 0.160 5.4 7.6 5.1 2.4 
 0.320 2.8 3.5 1.8 1.7 
 0.640 3.6 3.8 3.0 0.72 
8 1.28 2.0 0.58 1.9 1.0 
 2.56 1.6 2.5 1.1 1.8 
 5.12 0.48 0.47 0.23 0.68 
 10.2 1.3 0.20 0.41 0.16 
 
Table 5. Intraday and interday precision and accuracy using UV detection. 
Analyte Concentration of standard solution injected (μM) Intraday Interday 
  RSD (%) RE (%) RSD (%) RE (%) 
 0.0400 1.8 2.4 6.0 1.5 
 0.0800 6.6 6.4 0.12 6.5 
 0.160 1.5 1.4 4.7 0.95 
Analyte Concentration of standard solution injected (μM) Intraday Interday 
  RSD (%) RE (%) RSD (%) RE (%) 
 0.320 1.4 1.2 0.97 0.11 
 0.640 0.36 0.33 1.5 1.2 
 1.28 0.088 0.40 1.4 2.0 
 2.56 0.25 0.72 0.85 1.7 
1 5.12 1.2 0.50 0.90 1.5 
 10.2 0.22 0.70 0.41 1.2 
 20.5 0.52 0.78 0.32 0.94 
 41.0 0.037 1.1 0.42 0.70 
 81.9 0.033 0.19 0.23 0.26 
 164 0.067 0.051 0.27 0.073 
 328 0.21 0.29 0.061 0.26 
  
 0.0400 5.8 0.89 3.7 2.8 
 0.0800 0.49 0.43 1.3 0.86 
 0.160 1.3 6.0 1.6 4.4 
 0.320 1.7 0.010 0.19 0.020 
 0.640 0.94 0.92 1.0 0.24 
 1.28 0.47 1.2 1.2 1.4 
 2.56 0.38 1.0 0.85 1.4 
2 5.12 1.4 1.5 0.74 1.2 
 10.2 0.47 1.1 0.33 1.0 
 20.5 0.61 1.0 0.49 0.75 
 41.0 0.12 0.88 0.76 0.48 
 81.9 0.12 0.066 0.27 0.011 
 164 0.038 0.031 0.14 0.042 
 328 0.21 0.27 0.16 0.15 
  
 0.0400 2.9 11 2.8 8.5 
 0.0800 5.3 3.8 3.5 1.1 
 0.160 3.7 3.9 0.80 3.4 
 0.320 1.7 0.11 0.75 0.23 
 0.640 0.94 1.4 1.7 1.2 
 1.28 2.8 1.6 1.2 2.4 
 2.56 0.087 2.2 0.55 2.3 
3 5.12 1.3 2.1 0.63 1.9 
 10.2 0.52 1.4 0.26 1.4 
 20.5 1.0 1.5 0.65 1.1 
 41.0 0.10 0.90 0.75 0.52 
 81.9 0.16 0.019 0.30 0.050 
 164 0.063 0.057 0.15 0.053 
 328 0.20 0.33 0.19 0.20 
  
 0.160 0.91 12 2.2 9.2 
 0.320 1.7 2.5 4.2 4.9 
 0.640 1.2 0.58 1.2 2.0 
 1.28 4.3 1.4 1.7 2.9 
 2.56 0.49 2.5 2.0 3.0 
4 5.12 1.0 3.4 0.61 3.4 
 10.2 1.3 3.6 0.078 3.6 
 20.5 1.1 2.5 0.50 2.2 
Analyte Concentration of standard solution injected (μM) Intraday Interday 
  RSD (%) RE (%) RSD (%) RE (%) 
 41.0 0.49 1.8 0.50 1.4 
 81.9 0.0076 0.23 0.092 0.18 
 164 0.66 0.15 0.20 0.10 
 328 0.20 0.69 0.23 0.59 
  
 0.0400 4.4 5.0 8.4 0.31 
 0.0800 2.1 0.82 3.1 1.6 
 0.160 1.1 1.4 2.8 1.8 
 0.320 2.3 1.3 0.20 1.2 
 0.640 1.4 1.2 1.8 0.26 
 1.28 0.88 0.29 0.82 0.32 
 2.56 0.66 0.69 0.81 0.67 
5 5.12 1.1 0.48 0.29 0.60 
 10.2 0.29 0.16 0.35 0.0013 
 20.5 0.65 0.62 0.34 0.33 
 41.0 0.21 0.78 0.85 0.40 
 81.9 0.15 0.10 0.35 0.0011 
 164 0.10 0.0085 0.17 0.027 
 328 0.21 0.18 0.16 0.072 
  
 0.0400 4.4 7.1 6.1 0.97 
 0.0800 1.0 4.7 4.0 0.47 
 0.160 2.6 4.2 1.2 3.5 
 0.320 0.92 2.8 2.3 0.70 
 0.640 0.96 0.52 0.99 0.31 
 1.28 0.84 0.86 0.82 0.37 
 2.56 0.65 1.1 0.81 0.95 
6 5.12 0.84 0.59 0.43 0.83 
 10.2 0.15 0.13 0.43 0.17 
 20.5 0.64 0.89 0.28 0.59 
 41.0 0.21 0.93 0.95 0.55 
 81.9 0.14 0.12 0.38 0.032 
 164 0.11 0.015 0.19 0.056 
 328 0.21 0.21 0.17 0.11 
  
 0.0400 5.8 3.5 2.3 1.4 
 0.0800 6.8 6.5 2.9 3.4 
 0.160 2.9 4.4 3.4 3.2 
 0.320 1.9 1.5 1.2 0.29 
 0.640 0.75 0.16 1.2 0.40 
 1.28 1.2 1.2 1.4 0.38 
 2.56 0.76 0.16 1.0 0.078 
7 5.12 1.1 0.15 0.38 0.20 
 10.2 0.42 0.27 0.31 0.013 
 20.5 0.47 0.60 0.35 0.40 
 41.0 0.051 0.93 0.88 0.43 
 81.9 0.18 0.11 0.39 0.036 
 164 0.13 0.037 0.18 0.038 
 328 0.26 0.18 0.18 0.070 
  
Analyte Concentration of standard solution injected (μM) Intraday Interday 
  RSD (%) RE (%) RSD (%) RE (%) 
 0.0400 7.2 5.8 1.0 4.8 
 0.0800 4.1 1.4 6.1 0.62 
 0.160 1.8 2.5 1.2 2.4 
 0.320 0.035 1.5 1.0 0.28 
 0.640 1.0 1.5 1.4 1.2 
 1.28 0.55 1.4 1.6 0.18 
 2.56 0.93 0.46 0.99 0.39 
8 5.12 1.3 0.65 0.48 0.16 
 10.2 0.62 0.67 0.32 0.41 
 20.5 0.53 0.55 0.35 0.39 
 41.0 0.061 0.92 0.91 0.41 
 81.9 0.21 0.11 0.41 0.055 
 164 0.14 0.057 0.18 0.016 
 328 0.25 0.16 0.18 0.059 
 
3.2. Comparison of linear dynamic range with MS and UV detection 
 
One of the goals of this study was to compare MS and UV detectors for quantitative analysis of 
silymarin components (Fig. 2). The MS and UV detection techniques provided different linear 
dynamic ranges (Table 2, Table 3). The linear dynamic range for the MS analyses was 
determined to be 0.0800-10.2 μM for all compounds except compound 4, which demonstrated a 
linear dynamic range of 0.160-10.2 μM (Table 2). Above a concentration of 10.2 μM, signal 
saturation was observed with MS analysis for all of the silymarin constituents investigated. This 
saturation was not observed up to the highest concentration investigated when the UV detector 
was employed. For the UV data, the linear dynamic range was 0.0400–328 μM for all 
compounds except compound 4, and 0.160–328 μM for compound 4 (Table 3). Saturation at 
high concentration with MS analysis, particularly of highly polar small molecules, is a common 
occurrence [14]. However, contrary to the results observed in this study, it is generally the case 
that MS detection provides lower LLOQ than those observed with UV. Additional ionization 
methods were evaluated (positive and negative ESI and APCI) and positive mode HESI 
demonstrated the best sensitivity at the flow rates used in this study. For these studies, the S/N 
was observed to be higher with the use of the MS detector than the UV detector (Fig. S1). 
However, peak areas at low concentrations for multiple injections with MS were less repeatable 
than those measured with UV, leading to a better LLOQ with the UV detector. 
 
3.3. Quantitative analysis of compounds in silymarin mixtures 
 
A series of five commercial silymarin preparations from three different manufacturers was 
analyzed to determine their total content of compounds 1 through 8 as well as the absolute 
quantity of each compound individually in the mixtures. The composition of these mixtures 
varied significantly (at the 95% confidence interval, according to t-test, Table 6), both between 
different manufacturers and between batches from the same manufacturer. The two batches of 
silymarin extracts from Madaus showed the highest total content of all eight analytes (62% and 
70% by MS), while the two silymarin extracts from Sigma showed the lowest total analyte 
content (47% and 54%), and the Indena silymarin extract showed a total analyte content of 57%. 
For compound 4, the percent composition differed more between Madaus batches (1.4% and 
14%) than did the average percent composition for compound 4 for each of the manufacturers 
(2.5% for Sigma, 7.0% for Indena, and 7.8% for Madaus). These data, which were confirmed 
with both MS and UV detection (see Section 3.4), reaffirm previous studies of the variability 
amongst different commercial preparations of silymarin [15], which could be related to 
differences in growth conditions for the S. marianum plants [16] or general inconsistencies in 
extraction/processing procedures observed with many herbal medicines [17], [18]. For biological 
studies with S. marianum preparations, it is imperative to consider batch- and vendor-specific 
variation in individual and total flavonolignan content. 
 
Table 6. Comparison of UV and MS results for silymarin extracts. Percent composition of 
compounds 1-8 in various commercial silymarin extracts. 
Extract  Totala 1 2 3 4 5 6 7 8 
Madaus 
37501 UV 67 2.71 (0.01) 1.89 (0.02) 8.63 (0.14) 11.00 (0.03) 13.91 (0.02) 19.49 (0.08) 5.48 (0.02) 3.46 (0.02) 
 MS 70 2.65 (0.04) 1.95 (0.05) 8.79 (0.07) 14.18 (0.10) 13.85 (0.15) 19.38 (0.36) 5.58 (0.05) 3.53 (0.07) 
  
Madaus 
286061 UV 63 2.84 (0.04) 0.54 (0.01) 13.40 (0.09) 1.43 (0.02) 15.29 (0.05) 22.62 (0.13) 4.56 (0.03) 1.97 (0.02) 
 MS 62 2.81 (0.08) 0.52 (0.04) 13.33 (0.09) 1.44 (0.09) 15.17 (0.20) ALR 4.64 (0.07) 1.94 (0.03) 
  
Indena 
27691 UV 56 4.13 (0.02) 1.30 (0.01) 11.53 (0.06) 5.48 (0.04) 10.16 (0.02) 15.94 (0.11) 4.917 (0.001) 2.50 (0.02) 
 MS 57 4.13 (0.05) 1.22 (0.05) 11.60 (0.05) 7.02 (0.01) 10.29 (0.11) 15.68 (0.04) 4.92 (0.14) 2.52 (0.01) 
  
Sigma 
BCBJ0393V UV 46 3.17 (0.01) 0.84 (0.01) 10.15 (0.05) 3.27 (0.04) 9.17 (0.04) 13.60 (0.04) 3.84 (0.01) 1.97 (0.04) 
 MS 47 3.00 (0.08) 0.89 (0.06) 10.25 (0.05) 4.05 (0.07) 9.20 (0.07) 13.93 (0.20) 3.87 (0.07) 1.99 (0.09) 
  
Sigma 
05503PG UV 54 2.60 (0.03) 0.437 (0.003) 13.14 (0.05) 0.83 (0.02) 12.50 (0.03) 18.42 (0.06) 4.20 (0.01) 1.62 (0.01) 
 MS 54 2.61 (0.01) 0.40 (0.02) 13.08 (0.05) 0.82 (0.05) 12.51 (0.06) 18.49 (0.24) 4.22 (0.08) 1.70 (0.04) 
Shaded values for percent composition indicate a statistically significant difference (at the 95% confidence interval) 
between the percent composition measured by MS versus UV detection according to the t-test. Unshaded values 
showed no statistically significant difference between MS and UV data. 
ALR = above linear range of the MS detection method. 
BQL = below quantitation limit. 
ND = not detected. 
a Total percentage of the silymarin extract contributed by the eight compounds being measured in this study. 
 
3.4. Consistency of MS and UV results for quantitative analysis 
 
In most cases, the MS and UV data provided very similar results for the total content of 
compounds 1–8 in silymarin extracts (Table 6). For all compounds, with the exception of 
compound 4, no statistically significant difference was observed between concentrations 
determined with MS and UV (at the 95% confidence level, according to t-test) (Table 6). 
Significant differences were observed between MS and UV data for compound 4, due to matrix 
interference in the UV data as described in Section 3.5. 
 
3.5. Matrix effects 
 
Matrix effects were not observed in either MS (Fig. S2) or UV (Fig. S3) analysis for all of the 
compounds (1–8), except for compound 4, which exhibited a clear matrix effect in the UV 
analysis (Table 7). This matrix effect can be ascribed to contaminants with UV absorbance that 
co-elute in the peak front for compound 4 (Fig. S3). The UV contaminants are of different mass 
than compound 4, and are therefore, resolved from this compound with the MS detector and do 
not interfere with MS analysis (Fig. S2). For this reason, MS detection appears to be preferable 
for quantitative analysis of compound 4. 
 
Table 7. Examination of matrix effects by UV and MS for silymarin extracts. Each value 
represents the percent of the spiked analyte that was observed.a 
Extract  1 2 3 4 5 6 7 8 
Madaus 37501 UV 101 101 100 80 101 99 100 100 
 MS 99 98 93 82 89 86 99 92 
  
Madaus 286061 UV 99 101 100 76 96 94 99 102 
 MS 97 99 87 94 87 75 99 95 
  
Indena 27691 UV 103 102 105 80 106 106 103 103 
 MS 99 102 91 98 99 97 100 99 
  
Sigma BCBJ0393V UV 103 102 108 78 105 108 104 104 
 MS 102 100 97 97 99 96 104 100 
  
Sigma 05503PG UV 101 100 103 76 102 104 100 101 
 MS 100 98 90 95 94 83 102 94 
a Values close to 100 indicate no matrix effect observed. 
 
Matrix interference due to ionization suppression is a common problem in analyses via mass 
spectrometry [19]. In the case of silymarin, however, the lack of matrix interference indicates 
that ionization suppression is not an issue. This is likely due to the fact that the extract is 
somewhat purified by the manufacturer. Thus, either MS or UV appear to be acceptable 
detection techniques for quantitative analysis of silymarin components, with the exception of 
compound 4. 
 
3.6. Stability in DMSO 
 
A series of samples of the pure compounds from silymarin at 500 μM were examined by 
UHPLC-UV (after being exposed to DMSO at room temperature for 6 months). These DMSO-
exposed sample chromatograms are compared for analytes 1–4 in Fig. S4 and for analytes 5–8 in 
Fig. S5 with an identical analysis of the freshly prepared samples of the same batches of 
compounds that had been stored at 4 °C as a dry powder over the same time period. For each 
compound, a single new peak was observed in the DMSO-exposed sample. For compounds 3, 
and 5–8, the new degradation peak was greater than 8% of the total area. For the samples stored 
dry, no degradation products were detected. Consistent with similar findings on other classes of 
natural products [20], these data suggest that dry storage of silymarin components is preferable 
to storage in DMSO for maintaining compound integrity. However, for the standard and QC 
samples used in the quantitative study, no degradation peaks were observed, indicating stability 
in 1:1CH3CN:H2O over the time frame of the quantitative analysis. 
 
4. Conclusion 
 
In summary, herein is described a rigorous, validated method for the quantitative analysis of 
eight silymarin components in complex extracts. This method should be applicable to other S. 
marianum preparations, provided that appropriate controls are included to evaluate potential 
interference that may occur in more complex matrices [19]. For the studies described herein, 
both mass spectrometry and UV detection were effective for quantitative analysis. The UV 
detection method had the advantage of an expanded linear dynamic range, particularly at high 
concentrations, whereas the MS method was less prone to matrix interference for compound 4. 
Additionally, data are provided that indicate the importance of method of storage for maintaining 
integrity and biological activity of silymarin constituents. Not surprisingly, dry storage of 
constituents was preferable to prolonged storage in DMSO. Finally, these studies indicated that 
significant variation is observed in bioactive component concentrations for silymarin extract 
preparations among different manufacturers and even from different batches from the same 
manufacturer. Thus, analytical characterization is critical to establish constituent levels in 
silymarin preparations prior to conducting biological evaluations. The method published herein 
should prove useful towards conducting this characterization. 
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